Production (Stage)
Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.07M | -1.27M | 371.80K | -1.99M | -1.73M |
| Total Depreciation and Amortization | 46.50K | 54.10K | 61.80K | 44.50K | 32.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 625.30K | 625.20K | -1.29M | 781.50K | 701.40K |
| Change in Net Operating Assets | 324.60K | 400.80K | 346.40K | -334.70K | -476.10K |
| Cash from Operations | -77.70K | -186.40K | -505.60K | -1.50M | -1.47M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 45.70K | 45.70K | 18.70K | -- | -- |
| Total Debt Repaid | -18.60K | -19.80K | -21.70K | -50.20K | -47.40K |
| Issuance of Common Stock | -- | -- | 0.00 | 560.60K | 2.11M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -26.80K | -28.90K | -28.90K |
| Cash from Financing | 19.90K | 19.00K | -22.30K | 358.50K | 1.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -57.70K | -167.40K | -527.90K | -1.14M | 39.30K |